Prevention by an inhibitor of the l‐arginine‐nitric oxide pathway of the antiarrhythmic effects of bradykinin in anaesthetized dogs

Research output: Contribution to journalArticle

60 Citations (Scopus)


The intracoronary administration of bradykinin (25 ng kg−1 min−1) markedly reduces the severity of arrhythmias that occur during a 25 min occlusion of the left anterior descending coronary artery in chloralose, urethane anaesthetized dogs. This protection was abolished by the prior administration, by the same route, of NG‐nitro‐l‐arginine methyl ester (l‐NAME), an inhibitor of the l‐arginine‐nitric oxide pathway. The protective effect of bradykinin on reperfusion‐induced VF was not affected by l‐NAME. These results strongly suggest that the antiarrhythmic effect of bradykinin in this model is mediated by nitric oxide release. It also supports the concept that bradykinin might be a ‘primary mediator’ of the protective, antiarrhythmic effects of ischaemic preconditioning. 1993 British Pharmacological Society

Original languageEnglish
Pages (from-to)18-19
Number of pages2
JournalBritish journal of pharmacology
Issue number1
Publication statusPublished - Sep 1993



  • Nitric oxide
  • N‐nitro‐l‐arginine methyl ester (l‐NAME)
  • arrhythmias
  • bradykinin
  • myocardial ischaemia
  • preconditioning

ASJC Scopus subject areas

  • Pharmacology

Cite this